Novel small molecule therapeutics in rheumatoid arthritis

Targeting myeloproliferative neoplasms with JAK inhibitors

(2011) Animesh Pardanani et al.   CURRENT OPINION IN HEMATOLOGY

Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases

(2011) Omer N Pamuk et al.   ARTHRITIS RESEARCH & THERAPY

PI3K inhibition in inflammation: Toward tailored therapies for specific diseases

(2010) Alessandra Ghigo et al.   BIOESSAYS

Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis

(2010) Julie A Di Paolo et al.   Nature Chemical Biology

New Btk inhibitor holds promise

(2010) Rudi W Hendriks   Nature Chemical Biology

Targeting non-malignant disorders with tyrosine kinase inhibitors

(2010) Friedrich Grimminger et al.   NATURE REVIEWS DRUG DISCOVERY

The emerging mechanisms of isoform-specific PI3K signalling

(2010) Bart Vanhaesebroeck et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

(2010) Fiona E McCann et al.   ARTHRITIS RESEARCH & THERAPY

Tumor necrosis factor α-induced interleukin-32 is positively regulated via the Syk/protein kinase Cδ/JNK pathway in rheumatoid synovial fibroblasts

(2009) Se Hwan Mun et al.   ARTHRITIS AND RHEUMATISM

PI3K inhibitors for cancer treatment: where do we stand?

(2009) Sauveur-Michel Maira et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts

(2008) Yuan James Rao et al.   ACTA PHARMACOLOGICA SINICA